Skip to main content

Transplantation unit (Hematology)

There are two types of hematopoietic stem cell transplantation:

  • autotransplantation: autologous transplantation, using stem cells taken from the patient,
  • allotransplantation: allogenic transplantation,  using stem cells taken from a compatible brother or sister (known as a family or related transplant), or the stem cells of a voluntary and anonymous donor (an unrelated allogenic transplant). 

In practice, a transplant that follows a course of chemotherapy (the conditioning) takes place like a blood transfusion, the stem cells themselves lodging in the bone cavities where they multiply and ensure the restoral of the hematological and immune system. 

The first autologous transplantation of stem cells at the Jules Bordet Institute was carried out in 1981, followed by the first allogenic transplantation in 1984. 

Our programme was approved in 2009 by the Joint Accreditation Committee of the ISCT and EBMT or JACIE, recognising it as a centre of excellence for autologous and related and unrelated allogenic stem cell transplantations. 

The programme is growing, given the clear increase in transplant indications. We currently carry out about 35 autotransplants and 35 allotransplants a year. For the allotransplants we have a sterile unit with  6 laminar flow chambers.

Our programme is well supported by several specialists in medicine in addition to the hematologists specialising in transplantations, including infectiologists, intensivists and other specialists who possess the necessary skills to treat our patients. 

Also, in order to provide our patients with the most innovative treatment, the unit is engaged in clinical research
• Academic, in cooperation with the Belgian Hematological Society (BHS),  the EORTC, the LYSA, the IFM and the EBMT
• In cooperation with biotechnology firms for the handling of the graft in the framework of immunomodulation. 

Research projects


 

Project 1

A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with posttransplant cyclophosphamide in patients with a hematologic malignancy

Our team

Head of Department
Prof Dominique Bron – Hematologist (Lymphomas and Chronic Lymphoid Leukemias)

Head of Transplantation Unit
Prof Philippe Lewalle - Hematologist (Allotransplants)

Heads of the Clinics
- Prof Sebastian Wittnebel - Hematologist (Leukemias, Myelodysplasias and Allotransplants)

- Prof Nathalie Meuleman -  Hematologist (Multiple Melomas and Plasmocytary Disorders: Autotransplants)
- Prof Marie Maerevoet -   Hematologist (Lymphomas and Lymphoproliferative Disorders: Autotransplant

Resident doctors 
Dr Chloé Spilleboudt (Allotransplants)
Dr Marie Vercruysen (Autotransplants)
Dr Adriano Salaroli (Allogreffe)

Qualitician
Aurélie Timmermans
Olivier Carabin

Head Nurse
Patrick Crombez

Transplant coordination and health education nurse
Jaivenois Marie France

Transplant coordinator
Sandra Michiels

 Scientific publications

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Authors : Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lycke M, Flamaing J, Milisen K, Lobelle JP, Wildiers H
Year : 2019
Journal : Qual Life Res
Volume : 28
Pages : 663-676

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Authors : Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O
Year : 2019
Journal : Lancet Haematol
Volume : 6
Pages : e48-e57

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Year : 2019
Journal : J Clin Oncol
Pages : JCO1801010

Reciprocal immuno-biological alterations occur during the co-culture of natural killer cells and adipose tissue-derived mesenchymal stromal cells.

Authors : Najar M, Fayyad-Kazan M, Merimi M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Year : 2019
Journal : Cytotechnology
Volume : 71
Pages : 375-388

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Authors : Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, de Wilde V, Jaspers A, Pranger D, Deeren D, van Riet I, Vaes E, Beguin Y
Year : 2019
Journal : Bone Marrow Transplant

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more